AR079846A1 - Agentes terapeuticos derivados de bisfenol que contienen un grupo aquiral y su uso en el tratamiento del cancer - Google Patents

Agentes terapeuticos derivados de bisfenol que contienen un grupo aquiral y su uso en el tratamiento del cancer

Info

Publication number
AR079846A1
AR079846A1 ARP110100034A ARP110100034A AR079846A1 AR 079846 A1 AR079846 A1 AR 079846A1 AR P110100034 A ARP110100034 A AR P110100034A AR P110100034 A ARP110100034 A AR P110100034A AR 079846 A1 AR079846 A1 AR 079846A1
Authority
AR
Argentina
Prior art keywords
independently
formula
remainder
chg1
aromatic ring
Prior art date
Application number
ARP110100034A
Other languages
English (en)
Original Assignee
British Columbia Cancer Agency
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Columbia Cancer Agency, Univ British Columbia filed Critical British Columbia Cancer Agency
Publication of AR079846A1 publication Critical patent/AR079846A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/38—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings polycyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C15/00—Cyclic hydrocarbons containing only six-membered aromatic rings as cyclic parts
    • C07C15/12—Polycyclic non-condensed hydrocarbons
    • C07C15/16—Polycyclic non-condensed hydrocarbons containing at least two phenyl groups linked by one single acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/225—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/62—Halogen-containing esters
    • C07C69/63—Halogen-containing esters of saturated acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

También se proporcionan usos de dichos compuestos para el tratamiento de diversas indicaciones, que incluyen cáncer de prostata, así como métodos de tratamiento que involucran dichos compuestos. Reivindicacion 1: El uso de un compuesto que tiene la estructura de formula (1) o una sal farmacéuticamente aceptable de dicho compuesto, en donde: X es CH2, CHR1, o CR1R2; cada uno de R1 y R2 es independientemente alquilo C1-10 lineal o ramificado, sustituido o no sustituido, saturado o insaturado, o R1 y R2 juntos forman un alquilo C3-10 cíclico sustituido o no sustituido, saturado o insaturado, en donde el sustituyente opcional se selecciona del grupo que consiste en oxo, OJö', COOH, R3, OH, OR3, F, CI, Br, I, NH2, NHR3, NR32, CN, SH, SR3, SOR3, SO3H, SO3R3, SO2R3, OSO3R3, OR6, CO2R3, CONH2, CONHR3, CONHR6, CONR32, NHR6, OPO3H3, CONR3R6, NR3R6, y NO2; cada R3 es independientemente alquilo C1-10 no sustituido; cada R6 es independientemente acilo C1-10; al menos un Z de un anillo aromático es independientemente C-Q, al menos un Z del otro anillo aromático es independientemente C-T, CF, CCI, CBr, CI, COH, CG1, COG1, CNH2, CNHG1, CNG12, COSO3H, COPO3H2, CSG1, CSOG1, o CSO2G1, y cada Z restante es independientemente C-T, N, CH, CF, CCI, CBr, CI, COH, CG1, COG1, CNH2, CNHG1, CNG12, COSO3H, COPO3H2, CSG1, CSOG1, o CSO2G1; Q es como en resto de formula (2); J es G1, O, CH2, CHG1, CG12, S, NH, NG1, SO, SO2, o NR; M es H, CI, Br, CH2CI, CHCI2, CCI3, CH2Br, CHBr2, CBr3, o C:::CH; L es H o A-D; A es O, S, NH, NG1, N+H2, o N+HG1; D es H, G1, R, o como los restos de formulas (3), o un resto seleccionado de la TABLA 1; cada uno de q, r y t es independientemente 0, 1, 2, 3, 4, 5, 6 o 7; n es 0,1, 2, 3, 4, 5, 6, 7 u 8; T es un resto de formula (4); J2 es G1, O, CH2, CHG1, CG12, S, NH, NG1, SO, SO2, o NR; M2 es H, CH3, CI, Br, CH2CI, CHCI2, CCI3, CH2Br, CHBr2, CBr3, CH2OH, CH2OJö, G1, CH2OG1, CH2OR, CH2OG1OG1', G1OG1', G1OG1'OG1ö, CH2SG1, CH2NH2, CH2NHG1, CH2NG12, o C:::CH; L2 es H o A2-D2; A2 es O, S, SO, SO2, NH, NG1, N+H2, o N+HG1; D2 es H G1, R, restos de formulas (3), o un resto seleccionado de la TABLA 1; cada uno de u, y, j es independientemente 0, 1, 2, 3, 4, 5, 6 o 7; m es 0, 1, 2, 3, 4, 5, 6, 7 u 8; cada uno de Jö y Jö' es independientemente un resto seleccionado de la TABLA 1; cada G1, G1' y G1ö es independientemente alquilo C1-10 lineal o ramificado, o cíclico aromático o cíclico no aromático, sustituido o no sustituido, saturado o insaturado, en donde el sustituyente opcional se selecciona del grupo que consiste en oxo, OJö', COOH, R4, OH, OR4, F, CI, Br, I, NH2, NHR4, NR42, CN, SH, SR4, SO3H, SO3R4, SO2R4, OSO3R4, OR5, CO2R4, CONH2, CONHR4, CONHR5, CONR42, NHR5, OPO3H3, CONR4R5, NR4R5, y NO2; cada R4 es independientemente alquilo C1-10 no sustituido; cada R5 es independientemente acilo C1-10; R es acilo C1-10; y en donde uno o varios de los grupos OH está opcionalmente sustituido para reemplazar el H con un resto seleccionado de la TABLA 1, para preparar un medicamento para modular la actividad del receptor de androgenos (AR), con la condicion de que: i) cuando un Z en la posicion para respecto de X en el anillo aromático es C-Q; n es 1; J es G1, O, CH2, CHG1, CG12, S, NH, o NG1; Les A-D; A esO, S, NH, NG1, N+H2, o N+HG1; y D es H o un resto seleccionado de la TABLA 1, entonces el Z en la posicion para respecto de X en el otro anillo aromático es N, CH, CF, CCI, CBr, CI, COH, CNH2, COSO3H, COPO3H2, C-T, en donde cuando m es 1 y J2 es G1, O, CH2, CHG1, CG12, S, NH, o NG1, entonces L2 es H o A2-D2, en donde A2 es O, S, NH, NG1, N+H2, o N+HG1, y D2 es G1, R, un resto de formula (3), o C-Q, en donde cuando n es 1 y J es G1, O, CH2, CHG1, CG12, S, NH, o NG1, entonces L es H o A-D, en donde A es O, S, NH, NG1, N+H2, o N+HG1, y D es G1, R, un resto de formula (3); ii) cuando un Z en la posicion para respecto de X en el anillo aromático es CG1, COG1, CNHG1, CNG12, CSG1, CSOG1, o CSO2G1, entonces el Z en la posicion para respecto de X en el otro anillo aromático es N, CH, CF, CCI, CBr, CI, COH, CNH2, COSO3H, COPO3H2, C-T, en donde cuando m es 1 y J2 es G1, O, CH2, CHG1, CG12, S, NH, o NG1, entonces L2 es H o A2-D2, en donde A2 es O, S, NH, NG1, N+H2, o N+HG1; y D2 es G1, R, un resto de formula (3), o C-Q, en donde cuando n es 1 y J es G1, O, CH2, CHG1, CG12, S, NH, o NG1, entonces L es H o A-D, en donde A es O, S, NH, NG1, N+H2, o N+HG1, y D es G1, R, un resto de formula; y iii) cuando un Z en la posicion para respecto de X en el anillo aromático es C-T; m es 1; J2 es G1, O, CH2, CHG1, CG12, S, NH, o NG1; L2 es A2-D2; A2 es O, S, NH, NG1, N+H2, o N+HG1; y D2 es H o un resto seleccionado de la TABLA 1, entonces el Z en la posicion para respecto de X en el otro anillo aromático es N, CH, CF, CCI, CBr, CI, COH, CNH2, COSO3H, COPO3H2, C-Q, en donde cuando n es 1 y J es G1, O, CH2, CHG1, CG12, S, NH, o NG1, entonces L es H o A-D, en donde A es O, S, NH, NG1, N+H2, o N+HG1 y D es G1, R, un resto de formula o C-T, en donde cuando m es 1 y J2 es G1, O, CH2, CHG1, CG12, S, NH, o NG1, entonces L2 es H o A2-D2, en donde A2 es O, S, NH, NG1, N+H2, o N+HG1, y D2 es G1, R, o un resto de formula (3).
ARP110100034A 2010-01-06 2011-01-06 Agentes terapeuticos derivados de bisfenol que contienen un grupo aquiral y su uso en el tratamiento del cancer AR079846A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28223810P 2010-01-06 2010-01-06

Publications (1)

Publication Number Publication Date
AR079846A1 true AR079846A1 (es) 2012-02-22

Family

ID=44305151

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110100034A AR079846A1 (es) 2010-01-06 2011-01-06 Agentes terapeuticos derivados de bisfenol que contienen un grupo aquiral y su uso en el tratamiento del cancer

Country Status (6)

Country Link
US (1) US9388112B2 (es)
EP (1) EP2521707B1 (es)
JP (1) JP5940982B2 (es)
AR (1) AR079846A1 (es)
CA (1) CA2786319C (es)
WO (1) WO2011082487A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2307342B1 (en) 2008-07-02 2017-06-21 British Columbia Cancer Agency Branch Diglycidic ether derivative therapeutics and methods for their use
US9388112B2 (en) 2010-01-06 2016-07-12 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators
EP2693875A4 (en) * 2011-04-08 2014-10-22 British Columbia Cancer Agency BISPHENOL COMPOUNDS AND METHODS OF USE
US9365510B2 (en) 2012-04-16 2016-06-14 British Columbia Cancer Agency Branch Aziridine bisphenol ethers and related compounds and methods for their use
US9173939B2 (en) * 2013-05-10 2015-11-03 The University Of British Columbia Ester derivatives of androgen receptor modulators and methods for their use
KR20160054523A (ko) 2013-09-09 2016-05-16 브리티쉬 콜롬비아 캔써 에이전시 브랜치 암 영상화 및 치료용 할로겐화 화합물, 및 이들의 사용 방법
WO2016058080A1 (en) * 2014-10-14 2016-04-21 British Columbia Cancer Agency Branch Fluoro-chloro bisphenol ether compounds and methods for their use
WO2016058082A1 (en) * 2014-10-14 2016-04-21 British Columbia Cancer Agency Branch 18f compounds for cancer imaging and methods for their use
WO2016112455A1 (en) 2015-01-13 2016-07-21 British Columbia Cancer Agency Branch Heterocyclic compounds for cancer imaging and treatment and methods for their use
US10471023B2 (en) 2015-03-12 2019-11-12 British Columbia Cancer Agency Branch Bisphenol ether derivatives and methods for using the same
US20170298033A1 (en) * 2016-04-15 2017-10-19 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators
US11485713B2 (en) 2018-05-25 2022-11-01 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
CN108997093A (zh) * 2018-09-11 2018-12-14 中国科学院生态环境研究中心 一种双酚类化合物单取代脂肪醇及其合成方法
CA3115101A1 (en) 2018-10-18 2020-04-23 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
WO2020198712A1 (en) 2019-03-28 2020-10-01 Essa Pharma, Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
EP4135675A4 (en) 2020-04-17 2024-04-10 Essa Pharma, Inc. SOLID FORMS OF AN N-TERMINAL DOMAIN ANDROGEN RECEPTOR INHIBITOR AND USES THEREOF
WO2023046283A1 (en) 2021-09-22 2023-03-30 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Compounds and their use in a method for modulating ar (androgen receptor) transcriptional activity

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2571217A (en) 1951-10-16 Horace s
US2890189A (en) * 1954-06-14 1959-06-09 Johnson & Son Inc S C Alkali soluble resins and compositions containing the same
FR1389005A (fr) * 1963-01-09 1965-02-12 Bayer Ag Procédé perfectionné pour durcir des polyépoxydes
US4284574A (en) 1979-06-15 1981-08-18 Ciba-Geigy Corporation Diglycidyl ethers of di-secondary alcohols, their preparation, and curable compositions containing them
US4369298A (en) 1980-05-27 1983-01-18 Tokuyama Soda Kabushiki Kaisha Novel cured resin, process for production thereof, and lens composed of said resin from bis(alkyleneoxyphenyl)-diacrylate, bis(alkyleneoxyphenyl)diallyl ether, bis(alkyleneoxyphenyl)diallyl carbonate monomers
DE3170223D1 (en) 1981-01-13 1985-06-05 Teijin Ltd Ion-permeable composite membrane and its use in selective separation
PL135932B2 (en) 1983-11-04 1986-01-31 Politechnika Warszawska Process for manufacturing polyfunctional polyols
US5753730A (en) 1986-12-15 1998-05-19 Mitsui Toatsu Chemicals, Inc. Plastic lenses having a high-refractive index, process for the preparation thereof and casting polymerization process for preparing sulfur-containing urethane resin lens and lens prepared thereby
JPH0832844B2 (ja) * 1987-02-09 1996-03-29 パイロツトインキ株式会社 筆記板用不透明性インキ
EP0290860B1 (en) 1987-04-27 1995-01-25 Mitsubishi Gas Chemical Company, Inc. Thermosetting resin composition
JPH01503541A (ja) 1987-06-01 1989-11-30 ザ　ダウ　ケミカル　カンパニー ヒドロキシ芳香族化合物のプロパルギルエーテルの製造方法
US5155196A (en) 1987-06-01 1992-10-13 The Dow Chemical Company Polymer resulting from the cure of a preformed chromene-containing mixture
DE3821585A1 (de) 1987-09-13 1989-03-23 Hoechst Ag Positiv arbeitendes strahlungsempfindliches gemisch und daraus hergestelltes strahlungsempfindliches aufzeichnungsmaterial fuer hochenergetische strahlung
US4855184A (en) 1988-02-02 1989-08-08 Minnesota Mining And Manufacturing Company Radiation-curable protective coating composition
DE3939760A1 (de) 1989-12-01 1991-06-06 Bayer Ag Verfahren zur lackierung von kunststoffen, lackierte kunststoffe und die verwendung von hierzu geeigneten haftvermittlern
EP0515128A1 (en) 1991-05-23 1992-11-25 Konica Corporation Silver halide color photographic light-sensitive material
JPH0649473A (ja) 1992-08-04 1994-02-22 Asahi Chem Ind Co Ltd 冷媒組成物
DE4323512A1 (de) 1992-09-01 1994-04-28 Agfa Gevaert Ag Fotografisches Aufzeichnungsmaterial
JPH09176240A (ja) 1995-12-27 1997-07-08 Mitsubishi Chem Corp 光重合性組成物
ZA98900B (en) 1997-02-07 1998-08-03 Shell Int Research Process for the manufacture of epoxy compounds
JPH10316803A (ja) 1997-05-16 1998-12-02 Teijin Chem Ltd 難燃性樹脂組成物
IL125840A (en) 1997-08-22 2002-12-01 Teijin Chemicals Ltd Bromine compound production method
JPH11166087A (ja) 1997-12-04 1999-06-22 Teijin Chem Ltd 難燃性樹脂組成物
AU4494399A (en) 1998-06-30 2000-01-24 University Of British Columbia, The Inhibitors of androgen-independent activation of androgen receptor
US6245117B1 (en) 1998-08-07 2001-06-12 Ipposha Oil Industries Co., Ltd. Modifier of cellulose fibers and modification method of cellulose fibers
US6218430B1 (en) 1998-08-24 2001-04-17 Ligand Pharmaceuticals Incorporated Vitamin D3 mimics
JP3795679B2 (ja) 1998-09-01 2006-07-12 帝人化成株式会社 臭素化合物の製造方法
AU775928B2 (en) 1999-10-14 2004-08-19 Bristol-Myers Squibb Company Crystallographic structure of the androgen receptor ligand binding domain
US6534621B2 (en) 2000-05-18 2003-03-18 Dow Global Technologies Inc. Process for manufacturing a hydroxyester derivative intermediate and epoxy resins prepared therefrom
US6472436B1 (en) * 2000-07-17 2002-10-29 The Salk Institute For Biological Studies Methods for protecting cells from amyloid toxicity and for inhibiting amyloid protein production
WO2002018334A2 (en) 2000-08-31 2002-03-07 Theravance, Inc. Sodium channel modulators
US6646102B2 (en) 2001-07-05 2003-11-11 Dow Global Technologies Inc. Process for manufacturing an alpha-dihydroxy derivative and epoxy resins prepared therefrom
US20030092724A1 (en) * 2001-09-18 2003-05-15 Huaihung Kao Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic
US7344700B2 (en) 2002-02-28 2008-03-18 University Of Tennessee Research Corporation Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy
GB0324551D0 (en) 2003-10-21 2003-11-26 Karobio Ab Novel compounds
US8114381B2 (en) 2004-02-13 2012-02-14 The University Of British Columbia Radiolabeled compounds and compositions, their precursors and methods for their production
JP2005325301A (ja) * 2004-05-17 2005-11-24 Fuji Photo Film Co Ltd セルロースアシレートドープ組成物、およびセルロースアシレートフィルム
US20090105349A1 (en) 2004-08-18 2009-04-23 Warner-Lambert Company Llc Androgen modulators
JP2006208607A (ja) 2005-01-26 2006-08-10 Fuji Photo Film Co Ltd パターン形成材料、並びにパターン形成装置及び永久パターン形成方法
JP4753601B2 (ja) 2005-03-23 2011-08-24 旭化成イーマテリアルズ株式会社 感光性組成物
EP1717235A3 (en) 2005-04-29 2007-02-28 Bioprojet Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
FR2885904B1 (fr) 2005-05-19 2007-07-06 Aventis Pharma Sa Nouveaux derives du fluorene, compositions les contenant et utilisation
JP2007290980A (ja) 2006-04-21 2007-11-08 Shin Etsu Chem Co Ltd 含フッ素（メタ）アクリル酸エステル
TW200819421A (en) 2006-10-31 2008-05-01 Univ Nat Chunghsing The method of synthesizing biphenol A, BPA having di-alkoxyl group by using polycarbonate or its waste
KR20090115797A (ko) * 2007-02-20 2009-11-06 바스프 에스이 고굴절률 단량체, 이의 조성물 및 용도
EP2307342B1 (en) 2008-07-02 2017-06-21 British Columbia Cancer Agency Branch Diglycidic ether derivative therapeutics and methods for their use
AR079975A1 (es) 2010-01-06 2012-03-07 British Columbia Cancer Agency Agentes terapeuticos derivados de bisfenol u metodos para su uso, composiciones farmaceuticas y uso de los mismos
US9388112B2 (en) 2010-01-06 2016-07-12 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators
EP2693875A4 (en) 2011-04-08 2014-10-22 British Columbia Cancer Agency BISPHENOL COMPOUNDS AND METHODS OF USE
WO2012145328A1 (en) 2011-04-18 2012-10-26 The University Of British Columbia Dibenzylphenyl compounds and methods for their use
WO2012145330A1 (en) 2011-04-18 2012-10-26 The University Of British Columbia Fluorene-9-bisphenol compounds and methods for their use
WO2013028572A1 (en) 2011-08-19 2013-02-28 British Columbia Cancer Agency Branch Fluorinated bisphenol ether compounds and methods for their use
WO2013028791A1 (en) 2011-08-22 2013-02-28 British Columbia Cancer Agency Branch 18f compounds for cancer imaging and methods for their use
US9365510B2 (en) 2012-04-16 2016-06-14 British Columbia Cancer Agency Branch Aziridine bisphenol ethers and related compounds and methods for their use
US9173939B2 (en) 2013-05-10 2015-11-03 The University Of British Columbia Ester derivatives of androgen receptor modulators and methods for their use
US20150010469A1 (en) 2013-07-03 2015-01-08 British Columbia Cancer Agency Branch Bisphenol ether compounds with novel bridging groups and methods for their use
KR20160054523A (ko) 2013-09-09 2016-05-16 브리티쉬 콜롬비아 캔써 에이전시 브랜치 암 영상화 및 치료용 할로겐화 화합물, 및 이들의 사용 방법

Also Published As

Publication number Publication date
US20130131167A1 (en) 2013-05-23
US9388112B2 (en) 2016-07-12
CA2786319A1 (en) 2011-07-14
JP2013516435A (ja) 2013-05-13
EP2521707B1 (en) 2017-06-14
EP2521707A4 (en) 2013-07-24
WO2011082487A1 (en) 2011-07-14
EP2521707A1 (en) 2012-11-14
CA2786319C (en) 2019-03-12
WO2011082487A8 (en) 2013-01-17
JP5940982B2 (ja) 2016-06-29

Similar Documents

Publication Publication Date Title
AR079846A1 (es) Agentes terapeuticos derivados de bisfenol que contienen un grupo aquiral y su uso en el tratamiento del cancer
AR079975A1 (es) Agentes terapeuticos derivados de bisfenol u metodos para su uso, composiciones farmaceuticas y uso de los mismos
AR075396A1 (es) Derivados de quinazolinas y composiciones farmaceuticas
AR056986A1 (es) Aza heterociclos como inhibidores de quinasas. procedimiento de obtencion y composiciones farmaceuticas
CL2011002859A1 (es) Compuestos espironucleosidos, inhibidores del virus vhc; composicion farmaceutica de dichos compuestos; uso del compuesto para tratar la hepatitis c.
CU20110217A7 (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
CO6470846A2 (es) Derivados aminobut´ricos sustituidos como inhibidores de neprilisina
AR085039A1 (es) DERIVADOS DE PURINA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y SU USO EN LA PREPARACION DE MEDICAMENTOS PARA TRATAR ENFERMEDADES MODULADAS POR LA INHIBICION DE LA PI3K DE CLASE I Y/O mTOR
AR049399A1 (es) Difenilimidazopirimidina e -imidazol aminas como inhibidores de b-secretasa y metodo de obtencion de los mismos
AR062792A1 (es) Derivados azetidinona y metodos de uso de estos
AR051326A1 (es) Pirazolobenzodiazepinas disustituidas
NI201200012A (es) Profármacos que comprenden un conjugado de insulina - conector
AR076360A1 (es) Derivados de 3,3'-espiroindolinona y su uso en el tratamiento del cancer
AR067757A1 (es) Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales.
AR043998A1 (es) Acidos fenoxiaceticos
CR20120237A (es) Derivados del ácido carbamoil-metil-amino-acético sustituido como inhibidores de nep novedosos
AR063119A1 (es) Derivados de piridinonas sustituidas, composiciones farmaceuticas que los contienen y usos como antagonistas en trastornos asociados a receptores del tipo i de la hormona de melanina(mch-1 o mchr-1)
ECSP077648A (es) Tetrazolilos macrociclicos como inhibidores de serina proteasa de hepatitis c
AR081058A1 (es) Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer.
AR086357A1 (es) Derivados de indazol sustituidos activos como inhibidores de quinasas
AR052256A1 (es) Derivados de tetrahidropirano y su uso como agentes antidiabeticos
AR083879A1 (es) Analogos de aminoglicosidos antibacterianos, metodos de preparacion y uso como agentes terapeuticos
AR088728A1 (es) Moduladores de lxr como prodroga de imidazol
ES2660001T3 (es) Comprimido estable que contiene un derivado de 4,5-epoximorfinano
AR061574A1 (es) Derivados de 3- amino- imidazo [1,2-a] piridina

Legal Events

Date Code Title Description
FB Suspension of granting procedure